These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 11870242

  • 21. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group.
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [Abstract] [Full Text] [Related]

  • 25. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, Reid IR.
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [Abstract] [Full Text] [Related]

  • 26. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 27. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR.
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [Abstract] [Full Text] [Related]

  • 28. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 29. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 30. Annual zoledronic acid for osteoporosis.
    BMJ Group.
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [Abstract] [Full Text] [Related]

  • 31. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 32. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L.
    J Bone Miner Res; 2004 May 01; 19(5):737-44. PubMed ID: 15068496
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 01; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov 01; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 37. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 01; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 38. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.
    Cancer; 2012 Mar 01; 118(5):1192-201. PubMed ID: 21987386
    [Abstract] [Full Text] [Related]

  • 39. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP.
    J Bone Miner Res; 2011 Jan 01; 26(1):12-8. PubMed ID: 20645415
    [Abstract] [Full Text] [Related]

  • 40. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
    Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD.
    Kidney Int; 2008 Sep 01; 74(5):641-8. PubMed ID: 18509324
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.